TSHA Q2 2024 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-53.6% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$21M-1915.4% margin

Net Income

-$21M-1882.0% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-67.4%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$200M

Total Liabilities

$92M

Stockholders' Equity

$109M

Cash & Equivalents

$173M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$2M	-53.6%
Gross Profit	$1M	$2M	-34.3%
Operating Income	-$21M	-$23M	+8.9%
Net Income	-$21M	-$25M	+14.9%